481 filings
Page 22 of 25
4
lt9l2g
30 Nov 18
BioXcel Therapeutics / Frank Yocca ownership change
2:31pm
4
gncbiy1ia0swew pr3l
30 Nov 18
BioXcel Therapeutics / Richard I Steinhart ownership change
2:30pm
8-K
2y6xymyv9qxalv88v7x
14 Nov 18
BioXcel Therapeutics Reports Positive Results from Study in Agitated Schizophrenia Patients Supporting BXCL501 Clinical Development
8:44am
8-K
xfa4klf48sdk
9 Nov 18
BioXcel Therapeutics Reports Third Quarter 2018 Quarterly Results and Provides Business Update
7:35am
8-K
2eikqhw qfylre
5 Nov 18
First-in-human Phase 1b / 2 combination trial of BXCL701 and pembrolizumab (Keytruda®) expected to initiate in 4Q 2018
4:30pm
8-K
kol1kpqoqqayf
30 Oct 18
BioXcel Therapeutics Provides Update on the Clinical Advancement of BXCL501 for the Acute Treatment of Agitation
8:15am
8-K
phk65
26 Sep 18
BioXcel Therapeutics Expands Immuno-Oncology Partnership with Nektar into Clinical Development in Pancreatic Cancer
12:00am
SC 13D
szevd
14 Sep 18
BioXcel Therapeutics, Inc.
12:00am
8-K
m5rcnwo15ev
23 Aug 18
Entry into a Material Definitive Agreement
12:00am
8-K
2x0z3 vph6
8 Aug 18
BioXcel Therapeutics Reports Second Quarter 2018 Financial Results and Provides Business Update
4:02pm
8-K
srixa5sged
24 Jul 18
DPP8/9 Inhibition - The Primary Mechanism of BioXcel Therapeutics’ Lead Immuno-Oncology Asset, BXCL701, Highlighted in Peer-Reviewed Journal
5:20pm
8-K
y0yf7 gxy
27 Jun 18
BioXcel Therapeutics Reports Positive Results from Phase 1b Trial of Intravenously-dosed Dexmedetomidine Supporting BXCL501 Development
4:17pm
8-K
gom9ci16sctx2w
7 Jun 18
Regulation FD Disclosure
5:10pm
8-K
v51r byi5d
7 Jun 18
BioXcel Therapeutics Appoints Vincent J. O’Neill M.D., as Senior Vice President and Chief Medical Officer
4:01pm
8-K
w7t5x2tt5g qt
4 Jun 18
Results Support Further Development of triplet therapy
12:00am
8-K
1gzjwp sinmw9
21 May 18
Regulation FD Disclosure
4:21pm
8-K
bybgfl5gxdcg4g3t38
17 May 18
BioXcel Therapeutics Announces Data Presentation at ASCO 2018 Annual Meeting
4:17pm
10-Q
u4doyh hfwknfc8i5k
14 May 18
Quarterly report
4:20pm